From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides—Mechanisms and Applications
Marine Drugs · 2024
DOI: 10.3390/md22100449 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Marine Drugs, 2024. Verfasst von Du-Min Jo und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Marine Biodiversity of Korea (MABIK), Seochun 33662, Republic of Korea. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Aquatic Organisms, Peptides. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Marine Biodiversity Institute of Korea.
Abstract (Originalsprache)
To reveal potent ACE inhibitors, researchers screen various bioactive peptides from several sources, and more attention has been given to aquatic sources. This review summarizes the recent research achievements on marine peptides with ACE-inhibitory action and application. Marine peptides are considered excellent bioactives due to their large structural diversity and unusual bioactivities. The mechanisms by which these marine peptides inhibit ACE include competitive binding to ACEs’ active site, interfering with ACE conformational changes, and avoiding the identification of substrates. The unique 3D attributes of marine peptides confer inhibition advantages toward ACE activity. Because IC50 values of marine peptides’ interaction with ACE are low, structure-based research assumes that the interaction between ACE and peptides increased the therapeutic application. Numerous studies on marine peptides focused on the sustainable extraction of ACE-inhibitory peptides produced from several fish, mollusks, algae, and sponges. Meanwhile, their potential applications and medical benefits are worth investigating and considering. Due to these peptides exhibiting antioxidant, antihypertensive, and even antimicrobial properties simultaneously, their therapeutic potential for cardiovascular disease and other illnesses only increases. In addition, as marine peptides show better pharmacological benefits, they have increased absorption rates and low toxicity and could perhaps be modified for better stability and bioefficacy. Biotechnological advances in peptide synthesis and formulation have greatly facilitated the generation of peptide-based ACE inhibitors from marine sources, which subsequently offer new treatment models. This article gives a complete assessment of the present state of knowledge about marine organism peptides as ACE inhibitors. In addition, it emphasizes the relevance of additional investigation into their mechanisms of action, the optimization of manufacturing processes, and assessment in in vivo, preclinical, and clinical settings, underlining the urgency and value of this study. Using marine peptides for ACE inhibition not only broadens the repertory of bioactive compounds but also shows promise for tackling the global health burden caused by cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Marine Biodiversity of Korea (MABIK), Seochun 33662, Republic of Korea.
- Ocean and Fisheries Development International Cooperation Institute, Pukyong National University, Busan 48513, Republic of Korea.
- International Graduate Program of Fisheries Science, Pukyong National University, Busan 48513, Republic of Korea.
- Smart Food Manufacturing Project Group, Korea Food Research Institute, Wanju 55365, Republic of Korea.
- Department of Food Science and Technology, Pukyong National University, Busan 48513, Republic of Korea.
ORCID-Profile: Fazlurrahman Khan, Kyung Woo Kim, Grace Choi, Dae-Sung Lee, Young-Mog Kim
Förderung
- National Marine Biodiversity Institute of Korea
Zitieren
APA
Jo, D. M., Khan, F., Park, S. K., Ko, S. C., Kim, K. W., Yang, D., Kim, J. Y., Oh, G. W., Choi, G., Lee, D. S., & Kim, Y. M. (2024). From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides—Mechanisms and Applications. Marine Drugs. https://doi.org/10.3390/md22100449
Vancouver
Jo DM, Khan F, Park SK, Ko SC, Kim KW, Yang D, et al. From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides—Mechanisms and Applications. Marine Drugs. 2024. doi:10.3390/md22100449
BibTeX
@article{Jo2024,
author = {Jo, Du-Min and Khan, Fazlurrahman and Park, Seul-Ki and Ko, Seok-Chun and Kim, Kyung Woo and Yang, Dongwoo and Kim, Ji-Yul and Oh, Gun-Woo and Choi, Grace and Lee, Dae-Sung and Kim, Young-Mog},
title = {From Sea to Lab: Angiotensin I-Converting Enzyme Inhibition by Marine Peptides—Mechanisms and Applications},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22100449}
}
EUVIMED